SG Americas Securities LLC Invests $147,000 in Bicara Therapeutics Inc. (NASDAQ:BCAX)

SG Americas Securities LLC bought a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 8,411 shares of the company’s stock, valued at approximately $147,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Cinctive Capital Management LP acquired a new position in Bicara Therapeutics in the 3rd quarter worth $229,000. Barclays PLC acquired a new position in shares of Bicara Therapeutics during the 3rd quarter worth approximately $255,000. Jane Street Group LLC bought a new position in Bicara Therapeutics in the 3rd quarter valued at about $309,000. Teachers Retirement System of The State of Kentucky bought a new position in Bicara Therapeutics in the third quarter valued at about $358,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Bicara Therapeutics in the third quarter valued at about $462,000.

Bicara Therapeutics Trading Up 7.2 %

Shares of Bicara Therapeutics stock opened at $13.00 on Tuesday. The business has a 50 day moving average price of $15.66. Bicara Therapeutics Inc. has a 52-week low of $11.10 and a 52-week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14). As a group, analysts predict that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on BCAX. Wedbush assumed coverage on shares of Bicara Therapeutics in a report on Thursday, February 6th. They set an “outperform” rating and a $31.00 price target for the company. RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th. Rodman & Renshaw assumed coverage on shares of Bicara Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating and a $48.00 target price for the company. Finally, HC Wainwright increased their price objective on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $41.20.

Bicara Therapeutics Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.